Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study links the risk of ALCL to silicone breast implants

December 2, 2008
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Dutch researchers have found an association between anaplastic large T-cell lymphoma and silicone breast implants.

Dutch researchers have found an association between anaplastic large T-cell lymphoma and silicone breast implants.

Daphne de Jong, MD, PhD, from the pathology department at the Netherlands Cancer Institute in Amsterdam, and colleagues performed an individually matched case-control study that included 11 patients with ALCL, five of whom had received bilateral silicone breast implants one to 23 years before their ALCL diagnosis.

Dr. de Jong’s research group noted the presence of 12 diffuse large B-cell lymphomas, including one T-cell-rich B-cell lymphoma; five Burkitt lymphomas; 10 mucosa-associated lymphoid tissue-type lymphomas; three follicular lymphomas; three peripheral T-cell lymphomas; and two indolent B-cell lymphomas, unclassified.

Dr. de Jong and her colleagues determined that the odds ratio for ALCL associated with silicone breast implants was 18.2 (JAMA 300:2030-2035, 2008).

The researchers said, however, that the absolute risk for developing ALCL due to breast implants is low due to the rare occurrence of ALCL. They also said that more studies are needed to confirm their initial findings.

According to the American Society of Aesthetic Plastic Surgeons, there was a 295% increase in the number of women who had breast augmentation between the years 1997 and 2007.

Articles in this issue

Radiology resident compiles staging database
Study links the risk of ALCL to silicone breast implants
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma
Clara Bloomfield: Buck conventional wisdom always
New breast cancer program reduces time to treatment
PET/CT for prostate ca influences staging, treatment strategy
Racially-based disparities in ca on the rise, not due to smoking
ProStrakan offers patch to prevent nausea and vomiting
Online tool encourages families to bone up on genetics
Bevacizumab plus copper radiotracer shines as imaging probe
Coverting unresectable to resectable: Data still limited
AACR commits to Love/Avon Army of Women
Voters pass end-of-life measure in Washington state
Brachytherapy improves treatment in augmented women
Marathon effort to support cancer care
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
2 experts in this video
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.

Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC

Roman Fabbricatore
July 16th 2025
Article

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma

Russ Conroy
July 16th 2025
Article

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.

FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer

Tim Cortese
July 15th 2025
Article

Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.


The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC

Roman Fabbricatore
July 15th 2025
Article

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Related Content
Advertisement

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.

Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC

Roman Fabbricatore
July 16th 2025
Article

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma

Russ Conroy
July 16th 2025
Article

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.

FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer

Tim Cortese
July 15th 2025
Article

Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.


The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC

Roman Fabbricatore
July 15th 2025
Article

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.